Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) plus best supportive care (BSC) versus placebo (PBO) plus BSC as second-line (2L) therapy in patients (pts) in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study
Qin, Shukui ; Fang, Weijia ; Ren, ZhengGang ; Shuangyan, Ou ; Lim, Ho Yeong ; Zhang, Feng ; Choi, Hye Jin ; Tong, Jiandong ; Tao, Min ; Xu, Aibing ; Cheng, Ashley Chi Kin ; Lu, Chang-Hsien ; Chiu, Chang-Fang ; Wahid, Mohamed Ibrahim A. ; Kamble, Shital ; Norquist, Josephine M. ; Zhong, Wen Yan ; Li, Chen ; Chen, Zhendong
Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4088-4088 [Periódico revisado por pares]Texto completo disponível